WESTBOROUGH, Mass.--(BUSINESS WIRE)--GenomeQuest Inc. today announced the appointment of Robert Hoyt as an independent director of the firm, effective immediately. Mr. Hoyt’s appointment expands the Board to six directors.
“Bob’s enormous success as a B2B vertical search pioneer will add a critical perspective to our Board of Directors,” said Richard Resnick, Director and CEO. “We are very excited about his future contribution as a director and believe his counsel will be extremely valuable as GenomeQuest continues to expand its life science information business.”
Mr. Hoyt is currently the Chief Operating Officer of Eximo. Prior to that, he was the General Manager of Endeca Technologies which sold to ORACLE IN 2011. Bob has held executive roles at both start up and publicly held software companies. Bob is a mentor in the MIT VMS mentoring program where he advises entrepreneurial companies on growth strategies. Bob has an Industrial Engineering and Operations Research degree from University of Massachusetts, Amherst.
GenomeQuest is a global life science information and search company. Leveraging deep expertise in biology, genomics, and semantics, GenomeQuest produces GQ-Pat, a collection of nearly 300 million biological sequences found in the patent domain. GenomeQuest serves major nine of the top 10 pharmaceutical companies, four of the five top seed companies, and hundreds of biotech firms, IP legal teams, diagnostic labs, and universities around the world. Learn more at www.genomequest.com.